Episode Details

How did Terns Pharmaceuticals and its “hodgepodge” pipeline grab attention at the American Society of Hematology conference? Is Eli Lilly’s new drug making people lose too much weight? And what, exactly, is the Trump administration’s plan for reforming the National Institutes of Health?

First, we discuss all things ASH, particularly Tern’s chronic myeloid leukemia data,  Johnson & Johnson’s multiple myeloma data, and Fulcrum Therapeutics’ pill for sickle cell disease. We also get into the latest news in — what else? — obesity drugs.

Then, STAT reporters Megan Molteni and Anil Oza join for a conversation on the new series “American Science, Shattered,” which details this fissure and what it means for the future of the country’s scientific institutions.